Dr. Maeda-Chubachi has served as Novan’s senior vice president, medical, since March 2021 and vice president of medical dermatology since September 2017.
“The leadership and expertise that Dr. Maeda-Chubachi has brought to the company have been invaluable. She has played an instrumental role in the advancement of our development programs, and of particular note, SB206, which recently demonstrated positive topline data in our pivotal Phase 3 study,” said Paula Brown Stafford, president and CEO of Novan. “With the leadership of Dr. Maeda-Chubachi as our chief medical officer, I believe we are well-positioned to continue advancing our current development programs, unlock additional pipeline opportunities and build value for all stakeholders.”
Previously, she served as senior medical director at GlaxoSmithKline (GSK), and held clinical and medical affairs roles at Eli Lilly and Company and Pfizer. She was also an academic physician and dermatologist for 10 years, before entering the pharmaceutical industry.
“Over the course of my career, I have been involved with and led numerous development programs but none have I been as excited about as I am for SB206. The recently observed data from the positive B-SIMPLE4 trial gives me great confidence as we work towards a potential NDA filing and potential approval for the treatment of molluscum contagiosum,” said Dr. Maeda-Chubachi. “Additionally, we are working to build on this successful study as we work to continue to leverage our clinically proven NITRICIL technology platform to advance additional pipeline candidates.”